The IM resistance observed here in total CD34+ cells from two CML patients could be due to either BCR-ABL mutations on the CD34+ cells or the presence of most primitive CD34+/CD38- cells at a high percentage in CML samples compared with IM-sensitive CML samples used in this study. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.